HRT in 2026: What the FDA Warning Change Actually Means for You

In February 2026, the FDA did something it had not done in twenty-two years: it removed the boxed warning from menopausal hormone therapy. For more than two decades, every package of estrogen carried the agency's most severe safety label, warning of heart attack, stroke, breast cancer, and dementia. That warning shaped how a generation of women and their doctors thought about hormone therapy, and it kept many women who could have benefited from treatment away from it out of fear. The warning is now gone from most products. In my career I have not seen a bigger shift in women's health policy, and it has left a lot of patients unsure what is actually true now.

I want to walk through what changed, what did not, and what it means for the decision you might be weighing. Because the honest version is more nuanced than either the old warning or the headlines about its removal.

What is HRT?

Hormone replacement therapy, also called menopausal hormone therapy or HRT, replaces the estrogen your ovaries stop producing at menopause. As estrogen declines, many women experience hot flashes, night sweats, sleep disruption, vaginal dryness, mood changes, and accelerated bone loss. HRT treats these symptoms by restoring estrogen, and in women who still have a uterus, it adds a progestogen to protect the uterine lining.

There are two broad categories. Systemic HRT circulates throughout the body as a pill, patch, gel, or spray and treats the full range of menopausal symptoms. Local vaginal estrogen comes as a cream, ring, or tablet, treats genitourinary symptoms like dryness and painful intercourse, and delivers very little hormone into the bloodstream. That distinction matters, because the risks people associate with HRT come almost entirely from systemic therapy, not from local vaginal estrogen.

What actually changed in 2026

On February 12, 2026, the FDA approved labeling changes for the first six menopausal hormone therapy products, spanning all four categories of HRT.¹ The agency removed language about the risk of cardiovascular disease, breast cancer, and probable dementia from the boxed warning. This followed a November 2025 announcement, a July 2025 expert panel, and a public comment period, with 29 drug companies submitting proposed label changes.²

Here is the crucial part that headlines tend to skip. The FDA did not remove the endometrial cancer warning for systemic estrogen-alone products.^1,3 If you have a uterus and take estrogen without a progestogen, unopposed estrogen still raises the risk of endometrial cancer. That warning stays, and it is why women with a uterus take a progestogen alongside estrogen. The label change corrected an overcorrection; it did not declare hormone therapy risk-free.

Is HRT safe?

Safe for whom, started when, and in what form. That is the real answer, and it is why a single yes or no has always been misleading. The current evidence supports a favorable benefit-risk balance for most healthy women who start hormone therapy before age 60 or within 10 years of menopause.^3,5 This is the timing hypothesis, and it is the single most important concept in the entire HRT conversation.¹⁰ Started in that window, hormone therapy relieves symptoms and is associated with reduced all-cause mortality, fewer fractures, and possible cardiovascular and cognitive benefit. Started a decade or more after menopause, in a woman in her late 60s or 70s, the balance shifts and the risks weigh more heavily.

"Safe for most women" is not the same as "safe for everyone." Your age, how long ago you reached menopause, whether you have a uterus, your personal and family history of breast cancer and blood clots, and your cardiovascular risk all shape the equation. Removing the boxed warning did not hand out a blanket approval. It removed a one-size-fits-all scare from women for whom the science never justified it.

The real risks and benefits

The pattern running through this table is timing and formulation. A transdermal patch started at 52 is a different intervention, with a different risk profile, than an oral pill started at 68. When patients ask me whether HRT causes cancer, my answer is that estrogen-alone therapy does not meaningfully raise breast cancer risk, that combined therapy raises it modestly with longer use, and that the progestogen we add specifically prevents the endometrial cancer that unopposed estrogen would otherwise cause.

Types of HRT and how it is delivered

When patients ask about the pill versus the patch for perimenopause, the transdermal route is often my preference, particularly for women with any clot risk, because it bypasses first-pass liver metabolism and carries a lower risk of venous thromboembolism than oral estrogen. That is a genuine, evidence-based difference between forms, not a marketing distinction.

Bioidentical hormones: what the term actually means

"Bioidentical" may be the most misunderstood word in menopause care. It simply means a hormone with the same molecular structure as the one your body makes. Many FDA-approved products are bioidentical: estradiol patches, estradiol gel, and micronized progesterone (Prometrium) are all body-identical hormones, regulated, dose-verified, and covered by insurance. The confusion arises because the term is also used to market compounded bioidentical hormones, custom-mixed preparations that are not FDA-approved, not dose-verified, and not supported by evidence of added benefit. When I prescribe a bioidentical hormone, it is an FDA-approved one. I do not recommend compounded formulations, and neither do the major professional societies, because the dosing is unreliable and the safety is unproven.

Named products you may have heard of

A few brand names come up often, so here is what they are. Prometrium is micronized progesterone, the body-identical progestogen used to protect the uterine lining in women taking estrogen. Bijuva is an FDA-approved combination of body-identical estradiol and progesterone in a single capsule. These are regulated products with verified dosing, which is exactly what separates them from compounded alternatives.

If you cannot or prefer not to take hormones

Not everyone is a candidate for hormone therapy, and not everyone wants it. For those patients, 2026 offers effective non-hormonal options that did not exist a few years ago. A new class of drugs, the neurokinin receptor antagonists, targets the specific brain pathway that triggers hot flashes.

Fezolinetant (Veozah), approved in 2023, reduces hot flash frequency by roughly 60 percent in trials.⁶ Elinzanetant (Lynkuet), approved October 2025, reduced moderate-to-severe hot flashes by more than 73 percent by week 12 in its phase 3 OASIS trials, with the added benefit of improving sleep because it blocks a second receptor tied to nighttime waking.^7,8,13 Neither is a hormone, so both are options for women who cannot use estrogen, including many breast cancer survivors, though anyone with a cancer history should coordinate with their oncologist first.

Older non-hormonal options remain useful too: low-dose paroxetine is FDA-approved for hot flashes, and SSRIs, SNRIs like venlafaxine, and gabapentin all have evidence.⁹ Cognitive behavioral therapy helps with the distress and sleep disruption of vasomotor symptoms. These are real tools, not consolation prizes.

Timing: when to start, how long to stay on it

The timing hypothesis cuts both ways. Starting within the window, before 60 or within 10 years of menopause, is where the benefit-risk balance is most favorable. The old label instruction to use "the lowest effective dose for the shortest duration" has actually been removed as well, because it was not well supported by evidence and pressured women to stop treatment arbitrarily.³ There is no mandatory stop date. The decision to continue is one I revisit with each patient over time, weighing ongoing symptoms against her evolving risk profile, rather than enforcing a fixed cutoff.¹¹

Patients often ask how long HRT takes to work. Hot flashes usually improve within a few weeks, with fuller effect by two to three months. Vaginal symptoms treated with local estrogen can take a similar span. If you have started therapy and feel no difference after three months, that is worth discussing rather than assuming it will never work.

Does HRT cause weight gain?

Patients ask me this constantly, and the answer reassures most of them: hormone therapy itself is not a consistent cause of weight gain. The weight changes women notice around this time are driven mostly by the metabolic shifts of midlife and menopause itself, including a redistribution of fat toward the abdomen, not by the hormones we prescribe. Some women actually find that treating their symptoms improves sleep and energy enough to make weight management easier. HRT is not a weight-loss treatment, but it is not the culprit behind midlife weight gain that its reputation suggests. For women whose midlife weight gain is driven by insulin resistance, I discuss other approaches, including the GLP-1 medications covered in a separate guide.

What I tell patients

Timing is everything. If you are within 10 years of menopause or under 60 and have bothersome symptoms, you are likely in the window where the benefits most clearly outweigh the risks. That is the conversation to have now, not in five years.

The form matters. A transdermal patch is not the same as an oral pill when it comes to clot risk. If you have cardiovascular or clotting concerns, the delivery route is part of the decision.

If you have a uterus, you need a progestogen. Estrogen alone protects your symptoms but leaves your uterine lining unprotected. This is not optional, and it is the one warning the FDA deliberately kept.

Bioidentical does not mean compounded. FDA-approved bioidentical hormones are excellent options. Custom-compounded ones are unregulated and unproven. Do not confuse the two.

Non-hormonal options are real now. If hormones are not right for you, the neurokinin antagonists and other treatments genuinely work. You are not out of options.

The warning coming off does not mean the thinking stops. HRT is safer than a generation of women was told, and it is still a decision that deserves an individual conversation about your history, your symptoms, and your goals.

Frequently asked questions

Is HRT safe in 2026?

For most healthy women who start before age 60 or within 10 years of menopause, the FDA's 2026 decision reflects that HRT's benefits generally outweigh its risks. The agency removed the boxed warning language on cardiovascular disease, breast cancer, and dementia. "Safe for most" is not "safe for everyone," though. Your age, time since menopause, and personal history still shape the decision, and the endometrial cancer warning for estrogen-alone therapy remains in place.

What did the FDA actually change about HRT?

On February 12, 2026, the FDA removed language about cardiovascular disease, breast cancer, and probable dementia from the boxed warning on six menopausal hormone therapy products, with more to follow. It also removed the instruction to use the lowest dose for the shortest time. It did not remove the endometrial cancer warning for systemic estrogen-alone products in women with a uterus.

Does HRT cause weight gain?

No, hormone therapy is not a consistent cause of weight gain. The weight changes around menopause come mostly from the metabolic shifts of midlife and a redistribution of fat toward the abdomen, not from the hormones themselves. Some women find that better symptom control and sleep actually make weight easier to manage.

Does HRT cause cancer?

Estrogen-alone therapy does not meaningfully raise breast cancer risk and in some data lowers it. Combined estrogen-plus-progestogen carries a small increased breast cancer risk that grows with longer use. Unopposed estrogen raises endometrial cancer risk in women with a uterus, which is exactly why a progestogen is added to prevent it.

What are bioidentical hormones?

Bioidentical hormones have the same molecular structure as the ones your body makes. Many FDA-approved products are bioidentical, including estradiol patches and micronized progesterone (Prometrium). The term is also used to market compounded, custom-mixed hormones that are not FDA-approved or dose-verified. FDA-approved bioidenticals are recommended; compounded ones are not.

When should you start HRT, and how long can you stay on it?

The most favorable balance applies to starting before age 60 or within 10 years of menopause. There is no mandatory stop date; the old instruction to use the lowest dose for the shortest time has been removed. The decision to continue is revisited over time based on ongoing symptoms and your evolving risk profile.

What are the signs you might need HRT?

Common signals are frequent hot flashes and night sweats, sleep disruption, vaginal dryness or painful intercourse, mood changes, and new difficulty with concentration around the menopausal transition. Bone loss is a quieter reason. If symptoms are interfering with your sleep, work, or quality of life, that is the point to discuss options with a clinician.

What can I take instead of HRT?

Effective non-hormonal options include fezolinetant (Veozah) and elinzanetant (Lynkuet), new drugs that target the brain pathway driving hot flashes without using hormones. Low-dose paroxetine is FDA-approved for hot flashes, and venlafaxine, gabapentin, and cognitive behavioral therapy also help. These are real options, especially for women who cannot use estrogen.

References

1. US Food and Drug Administration. FDA Approves Labeling Changes to Menopausal Hormone Therapy Products. News release, February 12, 2026. fda.gov
2. US Food and Drug Administration. HHS Advances Women's Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy. News release, November 10, 2025. fda.gov
3. US Food and Drug Administration. FDA Requests Labeling Changes Related to Safety Information to Clarify the Benefit/Risk Considerations for Menopausal Hormone Therapies. Drug alerts and statements, November 2025. fda.gov
4. Writing Group for the Women's Health Initiative Investigators (Rossouw JE, Anderson GL, Prentice RL, et al). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333. doi:10.1001/jama.288.3.321. PMID 12117397
5. Society of Gynecologic Oncology. FDA Removes Black-Box Warnings on Hormone Replacement Therapy: guidance emphasizing initiation before age 60 or within 10 years of menopause. 2025-2026. sgo.org
6. Lederman S, Ottery FD, Cano A, Santoro N, Shapiro M, Stute P, Thurston RC, et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet. 2023;401(10382):1091-1102. doi:10.1016/S0140-6736(23)00085-5. PMID 36924778
7. US Food and Drug Administration. FDA approval of elinzanetant (Lynkuet) for vasomotor symptoms due to menopause. October 24, 2025.
8. Pinkerton JV, Simon JA, Joffe H, et al. Elinzanetant for the treatment of vasomotor symptoms associated with menopause: OASIS 1 and 2 randomized clinical trials. JAMA. 2024;332(16):1343-1354. doi:10.1001/jama.2024.14618. PMID 39172446
9. Panay N, Joffe H, Maki PM, et al. Elinzanetant for the treatment of vasomotor symptoms associated with menopause: a phase 3 randomized clinical trial (OASIS 3). JAMA Intern Med. 2025;185(11):1319-1327. doi:10.1001/jamainternmed.2025.4421. PMID 40920404
10. The Menopause Society. The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society. Menopause. 2023;30(6):573-590. PMID 37252752
11. "The 2022 Hormone Therapy Position Statement of The North American Menopause Society" Advisory Panel. Menopause. 2022;29(7):767-794. PMID 35797481
12. American College of Obstetricians and Gynecologists. Clinical guidance on menopausal hormone therapy and the timing hypothesis. Reaffirmed 2026. acog.org
13. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA. 2013;310(13):1353-1368. PMID 24084921

This article is educational and does not constitute medical advice or establish a physician-patient relationship. Decisions about hormone therapy require individualized assessment by a qualified clinician who knows your full history. Consult your own physician before starting, changing, or discontinuing any medication.